Yehlisa Ingozi Yokwehluleka Kwenhliziyo ngama-38%! I-Tirzepatide Ilungisa Kabusha Indawo Yokwelashwa Kwenhliziyo

I-Tirzepatide, i-novel dual receptor agonist (GLP-1/GIP), izuze ukunakwa okukhulu eminyakeni yamuva nje ngeqhaza layo ekwelapheni isifo sikashukela. Nokho, amandla ayo ezifweni zenhliziyo nemithambo yegazi nezinso ayavela kancane kancane. Ucwaningo lwakamuva lukhombisa ukuthi i-tirzepatide ikhombisa ukusebenza kahle okumangazayo ezigulini ezinokwehluleka kwenhliziyo ezinengxenyana ye-ejection elondoloziwe (HFpEF) ehlanganiswe nokukhuluphala kanye nesifo sezinso esingamahlalakhona (CKD). Ukuhlolwa komtholampilo kwe-SUMMIT kwembula ukuthi iziguli ezithola i-tirzepatide ziye zehla ngama-38% engcupheni yokufa kwenhliziyo nemithambo yegazi noma ukwehluleka kwenhliziyo ukuba kubi phakathi namaviki angama-52, kuyilapho izinkomba zokusebenza kwezinso ezifana ne-eGFR ziba ngcono kakhulu. Lokhu kutholakala kunikeza indlela entsha yokwelapha ezigulini ezinezinkinga eziyinkimbinkimbi ze-metabolic.

Emkhakheni wenhliziyo nemithambo yegazi, indlela yokusebenza ye-tirzepatide idlula ukulawulwa kwe-metabolic. Ngokwenza kusebenze womabili ama-GLP-1 nama-GIP receptors, kunciphisa umthamo wama-adipocyte, ngaleyo ndlela kwehlise umfutho wemishini wezicubu ezinamafutha enhliziyweni futhi kuthuthukiswe amandla e-myocardial metabolism namandla e-anti-ischemic. Ezigulini ze-HFpEF, ukukhuluphala nokuvuvukala okungapheli yizici ezibalulekile, futhi ukusebenza kwe-tirzepatide kwama-receptor amabili kucindezela ngempumelelo ukukhululwa kwe-cytokine evuvukalayo futhi kwehlise i-myocardial fibrosis, ngaleyo ndlela kubambezele ukuwohloka kokusebenza kwenhliziyo. Ukwengeza, ithuthukisa izinga lempilo elibikwe ngesiguli (njenge-KCCQ-CSS) namandla okuzivocavoca.

I-Tirzepatide nayo ikhombisa imiphumela ethembisayo ekuvikelweni kwezinso. I-CKD ivame ukuhambisana nokuphazamiseka kwe-metabolic kanye nokuvuvukala kwebanga eliphansi. Umuthi usebenza ngezindlela ezimbili: ukuthuthukisa i-glomerular hemodynamics ukunciphisa i-proteinuria, nokuvimbela ngokuqondile inqubo ye-renal fibrosis. Ocwaningweni lwe-SUMMIT, i-tirzepatide yenyusa kakhulu amazinga e-eGFR asekelwe ku-cystatin C futhi yehlisa i-albuminuria kungakhathaliseki ukuthi iziguli zine-CKD, okubonisa ukuvikelwa kwezinso okuphelele. Lokhu kutholakala kuvula indlela entsha yokwelapha isifo sikashukela kanye nezinye izifo zezinso ezingamahlalakhona.

Okuphawuleka nakakhulu inani eliyingqayizivele le-tirzepatide ezigulini “ezinonxantathu” wokukhuluphala, i-HFpEF, ne-CKD—iqembu elinokubikezela okubi ngokwejwayelekile. I-Tirzepatide ithuthukisa ukwakheka komzimba (inciphisa ukunqwabelana kwamafutha futhi ithuthukise ukusebenza kahle kwezicubu zemisipha) futhi ilungise izindlela zokuvuvukala, ngaleyo ndlela inikeze ukuvikeleka okuhlelekile kuzo zonke izitho eziningi. Njengoba izinkomba ze-tirzepatide ziqhubeka nokukhula, isilungele ukuba yindlela yokwelapha eyisisekelo ekulawulweni kwezifo ze-metabolic ezine-comorbidities.